Vaso²R: Early Argipressin in Norepinephrine-Refractory Vasoplegic Shock

Phase 3, randomised, double-blind trial in Vasoplegia comparing Argipressin (Reverpleg) with Placebo (0.9% sodium chloride) (2 arms). Primary endpoint: Hierarchical composite outcome of 30-day mortality, renal replacement therapy use within 30 days, and vasopressor use persistence within 15 days. Planned start Jun 2025; status: authorised.